FINWIRES · TerminalLIVE
FINWIRES

$JAZZ

8 stories mentioning JAZZ

Every FINWIRES story that references JAZZ, newest first.

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday. Merck shares were down 1%.AstraZeneca (AZN) said Friday the US Food and Drug Administration approved Truqap in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive prostate cancer. AstraZeneca shares were declining 1.6%.Jazz Pharmaceuticals (JAZZ) shares fell 1.2% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped past 7%.

$AVTX$AZN$JAZZ$MRK
Sectors

Sector Update: Healthcare Stocks Softer in Afternoon Trading

Healthcare stocks edged lower Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing about 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Jazz Pharmaceuticals (JAZZ) shares fell 1.3% after it said a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet its primary endpoint.Avalo Therapeutics' (AVTX) lead drug abdakibart is now a cleaner immunology story following positive phase 2 trial data to treat skin disease hidradenitis suppurativa, BofA Securities said. BofA started coverage of the stock with a buy rating and a price target of $35. Avalo shares jumped 6%.Cogent Biosciences (COGT) said Bezuclastinib showed "rapid and deep" clinical benefit in advanced systemic mastocytosis patientsfollowing detailed and updated trial results. Shares rose 1.6%.

$AVTX$COGT$JAZZ
Sectors

Sector Update: Healthcare

Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index decreasing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Jazz Pharmaceuticals (JAZZ) shares fell 1.6% after it said Friday that a phase 3 trial of Zepzelca in second-line metastatic small cell lung cancer failed to meet the primary overall survival endpoint, whether used alone or in combination with irinotecan, versus the investigator's choice of chemotherapy.

$JAZZ
Wire

BofA Securities Raises Price Target on Jazz Pharmaceuticals to $307 From $281, Maintains Buy Rating

Jazz Pharmaceuticals (JAZZ) has an average rating of overweight and mean price target of $259.28, according to analysts polled by FactSet.(covers e281quity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $234.28, Change: $+5.09, Percent Change: +2.22%

$JAZZ
Research

Bernstein Initiates Coverage on Jazz Pharmaceuticals With Market Perform Rating

Jazz Pharmaceuticals Public Company (JAZZ) has an average rating of overweight and mean price target of $256.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$JAZZ
Research

UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $307 From $188

Jazz Pharmaceuticals (JAZZ) has an average rating of overweight and mean price target of $245.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$JAZZ
Wire

Jazz Pharmaceuticals Delivered Strong Q1 on Broad-Based Portfolio Growth, RBC Says

Jazz Pharmaceuticals (JAZZ) delivered a "strong" Q1 as broad-based growth across its commercial portfolio and pipeline reinforced confidence in the health of the business, RBC Capital Markets said in a report Wednesday.Q1 revenue of about $1.07 billion topped the consensus estimate of $978 million, driven by strength across nearly "all major assets," the report said, adding that the company maintained its 2026 revenue guidance of $4.25 billion to $4.5 billion, though results could exceed that range.Concerns remain around future generic competition for the "oxybate franchise" and competitive pressures in oncology, though the firm believes the company's strong execution provides a cushion against potential "erosion." RBC estimates 2026 sales for Xywav at about $1.73 billion with expected "gradual decline" in later years, according to the report.The report also highlighted the company's "oncology pipeline" as a key focus, citing potential expansion opportunities for Ziihera, strong "initial uptake" for Modeyso, better-than-expected Zepzelca revenue and 15% year-over-year Epidiolex sales growth to $250 million driven by sustained epilepsy-related demand and international expansion.RBC maintained an outperform rating on Jazz Pharmaceuticals and raised its price target to $258 from $195.Price: $223.80, Change: $+11.54, Percent Change: +5.44%

$JAZZ
Insider Trading

Jazz Pharmaceuticals Insider Sold Shares Worth $1,219,980, According to a Recent SEC Filing

Bruce C Cozadd, Director, on May 01, 2026, sold 6,000 shares in Jazz Pharmaceuticals (JAZZ) for $1,219,980. Following the Form 4 filing with the SEC, Cozadd has control over a total of 378,682 ordinary shares of the company, with 378,682 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1232524/000119321026000011/xslF345X05/edgardoc.xml

$JAZZ
JAZZ News | FINWIRES